Drug Patent Expiry Opportunities for API & Generic Companies Discussed in New Study Published at MarketPublishers.com
14 Mar 2012 • by Natalie Aster
LONDON – With products worth USD 50 billion having witnessed the entry of generic competition, the year 2012 presented a bonanza for generic and active pharmaceutical ingredient (API) companies. By virtue of being the first to file, a select few firms which planned well in advance for these patent expiries have captured the full benefits of these patent expiries.
To partner with these FTF companies, API producers should be prepared in advance with the most optimized manufacturing process. With so many new launches occurring every year, it is always hard for API/generic companies to screen which product would continue to grow unabated by competition.
New research study “Underappreciated Megablockbuster Drug Patent Expiry Opportunities for API Manufacturers and Generic Drug Companies” elaborated by PharmaIntellect has been recently published by Market Publishers Ltd.
Underappreciated Megablockbuster Drug Patent Expiry Opportunities for API Manufacturers and Generic Drug Companies
Published: March, 2012
Price: US$ 5.000,00
The report shortlists five new molecular entities, which would reach mega blockbuster status by the end of patent expiry and by virtue of being best in class products, the impact of therapeutic substitution, which would further aid the volume sales scale up to double the pre-expiry levels.
More new research studies by the publisher can be found at PharmaIntellect page.